Targeting ZIP12-mediated Zn 2+ signaling as a treatment for pulmonary hypertension
Science Translational Medicine · 2026
DOI: 10.1126/scitranslmed.aee0680 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Lan Zhao und 18 weiteren Autor:innen. Beteiligte Einrichtung: National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Signal Transduction, Zinc, Cation Transport Proteins. Die Arbeit nennt 47 Literaturangaben. Gefördert von: British Heart Foundation.
Abstract (Originalsprache)
ZIP12, a membrane-bound zinc importer, is up-regulated in the remodeled pulmonary arterioles of patients with pulmonary arterial hypertension (PAH). Genetic deletion of its encoding gene, Slc39a12 , ameliorates the disease in rodent models. Here, we show that ZIP12 overexpression in human pulmonary artery smooth muscle cells (PASMCs) increased intracellular labile Zn 2+ and promoted proliferation. ZIP12 siRNA knockdown attenuated pulmonary hypertension in rodent models. We developed a humanized anti-ZIP12 monoclonal antibody, APL-9796, that normalized intracellular Zn 2+ concentration, suppressed proliferation in fibroblasts derived from patients with PAH and PDGF-stimulated PASMCs, and reduced PDGF-induced cytoskeletal remodeling in PASMCs and contractility in PASMCs and engineered pulmonary artery tissues. APL-9796 showed dose-dependent efficacy in humanized Slc39a12 rats, improving cardiopulmonary parameters after induction of pulmonary hypertension and was well tolerated in phase 1 clinical studies. Transcriptomic profiling revealed modulation of several molecular pathways, including those involving AMPK, PPAR, and PI3K-Akt. ZIP12-driven labile Zn 2+ signaling underpins the pathogenesis of PAH. Targeting ZIP12 with APL-9796 offers a promising therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK.
- Apollo Therapeutics Limited, Cambridge, UK.
- Research Center of the Hospital Center of the University of Montreal (CR-CHUM) and Faculty of Medicine, University of Montreal, Montreal, QC, Canada.
ORCID-Profile: Lan Zhao, Stephanie Hopley, Chien-Nien Chen, Chongyang Xie, Nicoleta Baxan, Ali Ashek, Lin Zhao, Adam Fellows, Daria S Kostyunina, Eduardo Oliver, Shu Ning, Guy Rutter, Paul Hamblin, Martin R Wilkins
Förderung
- British Heart Foundation
Zitieren
APA
Zhao, L., Hopley, S., Chen, C. N., Kibreab, I., Xie, C., Baxan, N., Ashek, A., Zhao, L., Fellows, A., Kostyunina, D. S., Oliver, E., Wang, L., Ning, S., Rutter, G., Gorelik, J., Gurrell, R., Butt, R., Hamblin, P., & Wilkins, M. R. (2026). Targeting ZIP12-mediated Zn 2+ signaling as a treatment for pulmonary hypertension. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aee0680
Vancouver
Zhao L, Hopley S, Chen CN, Kibreab I, Xie C, Baxan N, et al. Targeting ZIP12-mediated Zn 2+ signaling as a treatment for pulmonary hypertension. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aee0680
BibTeX
@article{Zhao2026,
author = {Zhao, Lan and Hopley, Stephanie and Chen, Chien-Nien and Kibreab, Iyobel and Xie, Chongyang and Baxan, Nicoleta and Ashek, Ali and Zhao, Lin and Fellows, Adam and Kostyunina, Daria S and Oliver, Eduardo and Wang, Lei and Ning, Shu and Rutter, Guy and Gorelik, Julia and Gurrell, Rachel and Butt, Richard and Hamblin, Paul and Wilkins, Martin R},
title = {Targeting ZIP12-mediated Zn 2+ signaling as a treatment for pulmonary hypertension},
journal = {Science Translational Medicine},
year = {2026},
doi = {10.1126/scitranslmed.aee0680}
}
EUVIMED